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Abstract: Glucagon circulates in concentrations in the low picomolar range, which is demanding
regarding the sensitivity of the methods for quantification applied. In addition, the differential
and tissue specific proteolytic processing of the glucagon precursor and the presence in of several
glucagon-like sequences, not only in the precursor of glucagon, but also in a number of other peptides
of the glucagon-secretin family of peptides, put special demands on the specificity of the assays.
Finally, experience has shown that unspecific interference of plasma components has presented
additional problems. All of these problems have resulted in a lot of diverging results concerning
measured and reported glucagon responses in both humans and experimental animals that have and
still are causing considerable debate and controversy. There is very solid evidence that glucagon
is an important hormone in human and mammalian metabolism, but its precise physiological role
in glucose and lipid metabolism and in metabolic disease has been difficult to establish, not least
because of these difficulties. It was our purpose with this review to discuss the methods of glucagon
quantification and discuss pitfalls and sources of error. We also reviewed some of the dogmas
regarding glucagon secretion in the light of the methodological difficulties.
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1. Introduction
Because of the low concentrations of circulating glucagon, direct measurements in plasma had to
await the development of sufficiently sensitive techniques, and the advent of the radio-immunoassays
allowed Roger Unger in Dallas, Texas, who was in close contact with Berson and Yalow, to build
on their experience from the development of the insulin assay [1], enabling him (and Eisentraut) to
publish the first glucagon assay, almost simultaneously with the insulin assay, in 1959 [2]. A full
publication appeared in 1961 [3] and the assay was reported to have a detection limit of 50 pg/mL
(16–17 pmol/L)- sensational for the time, but not quite enough to reliably measure physiological
levels in humans. In the following years, Unger and the Unger lab made numerous important
contributions to our knowledge of glucagon’s physiology, including the importance of glucose for
its secretion [4–6], the effect of starvation [5], diagnosis of glucagon-secreting tumors [7] and the
importance of amino acids for its secretion [8]. Assay improvements along the way made it possible to
study meal response in both healthy and in individuals with type 2 diabetes, resulting in the citation
classic by Müller et al. from 1970 [9], showing suppression of glucagon by carbohydrates but lack of
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suppression and hypersecretion of glucagon in patients with T2DM. The group was subsequently
fortunate enough to develop a particularly sensitive and specific antiserum from rabbit 30 K with
improved sensitivity and specificity [10], and the glucagon assay based on this antiserum, which was
commercialized, dominated the field of glucagon research for decades. Eventually, other assays with
similar or improved specificity and sensitivity were developed.
2. The Specificity of the Glucagon Assays
What were the particular specificity problems of the glucagon radioimmunoassays? Early work
from Unger’s laboratory indicated that there was glucagon immunoreactivity in the gut [11,12],
and work by Valverde from Unger’s group [13] and also from Buchanan in North Ireland [14], as well
as Holst et al. in Copenhagen [15] indicated that there were glucagon-like substances secreted from
the gut; mainly two components, differing in size both of which differed significantly from pancreatic
glucagon. Antisera were developed that did not react with these intestinal moieties at all [10,16,17],
whereas others appeared to react equally with the two forms intestinal forms and with glucagon,
although all antisera were raised against glucagon. The intestinal molecules were called gut-GLI
(gut glucagon-like immunoreactivity) or enteroglucagon [18]. Research from several groups finally
revealed that both intestinal moieties contained the entire glucagon sequence [19]. After isolation and
sequencing, the larger of the two molecules, which was designated glicentin (“GLI” for glucagon-like
immunoreactivity, “cent” because Sundby, who first isolated the compound, thought it contained
100 amino acids [20], “-in” to make it sound hormone-like), was shown [21] to consist of 69 amino
acids, of which glucagon occupies positions 33–61. The smaller one, of 37 amino acids with glucagon
occupying to first 29 amino acids [22,23], was named oxyntomodulin by Bataille, who had found
inhibitory activity of this compound on acid secreting oxyntic glands) in experimental animals [24].
In further research, the peptide occupying positions 1–30 of glicentin (GRPP, glicentin-related
pancreatic polypeptide) was isolated also from the pancreas and demonstrated to be released in
parallel with glucagon [25], and intact glicentin was also found in pancreatic extracts [26]. Therefore,
it was proposed that glicentin was at least a fragment of proglucagon, the glucagon precursor [25].
Proglucagon would be formed in both the intestinal mucosa and in the pancreas, but would undergo
differential post-translational processing, leading to formation of glicentin and oxyntomodulin (but
no glucagon) in the gut, and GRPP, glucagon, and a small C-terminal fragment in the pancreas.
Upon cloning of the gene encoding proglucagon [27,28], this concept was found to be correct, but the
proglucagon sequence also revealed the presence of two additional glucagon-related sequences in the
remaining part of the precursor, henceforth designated the glucagon-like peptides-1 and -2. As was
subsequently demonstrated, this part of the glucagon precursor, the so-called major proglucagon
fragment (residues no 72–160), also undergoes differential tissue specific processing, releasing the two
glucagon-like peptides from the gut, whereas it is secreted mainly as a single molecular entity from the
pancreas [29,30]. Looking at the proglucagon processing (Figure 1), is becomes clear that the glucagon
sequence is present in several molecular entities, which all may be present in the circulation and in the
various tissues [31].
From the pancreas: the fully processed 29-amino acid glucagon peptide. In addition, there
is some formation of proglucagon 1-61, comprising the glucagon sequence + GRPP (+ two basic
residues removed during proteolytic processing) [32]. Under normal circumstances, proglucagon
1–160 (or maybe 1–158) is not known to be secreted, but the product may be difficult to recover during
plasma sample processing and may be secreted in individuals with mutations of the prohormone
convertases [33].
From the gut [34]: Glicentin, proglucagon 1–69. Glicentin is thought to have a rather prolonged
half-life compared to the other proglucagon-derived peptides but is otherwise secreted in near
equimolar amounts with GLP-1 and GLP-2. Oxyntomodulin is also secreted, usually in a ratio of 1:2 or
1:3 compared to glicentin. It is usually thought of as a processing product of glicentin, and it is stored
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in the L-cells in the same ratio as it is secreted [35]. Glucagon itself has also been found to be produced
in the gut under certain circumstances, usually in small amounts [36] (see below).
Figure 1. Proglucagon processing and measurement of glucagon by antibodies. The numbers refer to
the numbering of the residues in proglucagon. Glucagon 1–61 may also be formed in the pancreas.
3. The Glucagon Radioimmunoassay
The essential ingredients in a radioimmunoassay are [37]:
(1) A pure, correct standard. This is uncomplicated for a short peptide such as glucagon.
(2) A radiolabeled ligand. Unlike earlier, 125-I is generally used because of its safety and reasonable
half-life. The iodine is incorporated by oxidation into a tyrosine residue of the molecule, and the
essential maneuver is to ensure mono-iodination (better stability) and high specific activity, i.e., lack
of admixture of un-labeled peptide. 131-I was previously used for glucagon radioimmunoassays,
but is more sensitive for instability (e.g., decay catastrophe) compared to 125-I. Addition of aprotinin
(trasylol) was previously important to reduce protease-dependent degradation of the tracer but may
not be necessary for 125-I. Today, it is possible to purchase mono-iodinated glucagon tracer with high
specific activity, but the tracer quality is always an important and potentially varying factor;
(3) An antibody with suitable affinity and specificity. High affinity is essential for the sensitivity.
With appropriate immunization procedures it is possible to generate antibodies of very high affinity,
and although such antisera are by nature polyclonal and have varying affinities, presence of even a
very small fraction of antibodies with high affinity will suffice to establish a sensitive assay, because
only this little fraction of all of the clones will be able to participate in ligand binding when the reagents
are diluted to fit the concentrations of glucagon in plasma. Some of these clones may also have the
desired specificity, but this always needs to be established by careful specificity testing.
How do we select antibodies with an appropriate specificity? Upon immunization with full length
glucagon, a mid-region of the molecule usually shows up as antigenic determinant [38]. Such antibodies
against a mid-region will measure all moieties containing the glucagon sequence, including those
from the gut. These antibodies may be designated cross-reacting. Antibodies against the N-terminus
of glucagon, which can be generated by immunization with N-terminal fragments of the molecule,
will necessarily cross-react with oxyntomodulin and therefore be useless in a radioimmunoassay.
Antibodies against the C-terminus, on the other hand, will cross-react exclusively with glucagon from
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the pancreas and with proglucagon 1–61, which is secreted in parallel with glucagon itself, and also
has some glucagon bioactivity [32]. It is normally present in very small amounts, except in patients
with renal disease, where this component may be the dominating circulating moiety. If glucagon also
is secreted from the gut, this will of course also contribute. The famous antiserum, 30k, from the
Unger lab, is a C-terminal antibody, and thus, is the antiserum 4305 used in the authors’ laboratory
for many years. Indeed, most of our knowledge about glucagon physiology is obtained with such
C-terminal antibodies, sometimes designated specific antibodies. The cross-reacting antibodies, on
the other hand, measure glicentin and oxyntomodulin, and by subtracting the results obtained with a
C-terminal assay from those obtained with a cross reacting assay, one may obtain a measure of the
enteroglucagons (glicentin and oxyntomodulin) [39]. The strongest stimulus for the secretion of the
enteroglucagons is luminal carbohydrates [40], and if carbohydrates in a meal are the predominating
component, pancreatic secretion will be normally be suppressed, and the measured concentration will
therefore mainly reflect the contribution of the enteroglucagons. Unfortunately, it has happened many
times in the literature that investigators have not been aware of these differences, which means that
many reported results are inaccurate. Indeed, unless specific reference is made to the specificity of the
assay, reported findings regarding glucagon secretion should not be considered accurate.
3.1. Unspecific Interference
Whether the binding region of glucagon antibodies shows cross-reaction with plasma proteins
is unknown, but it is a fact that most (virtually all) glucagon antibodies react unspecifically with
proteins in plasma, causing a matrix effect. This can be quite pronounced and is therefore best avoided.
It has been tried to use plasma from pancreatectomized individuals to correct for this error [41],
but these patients may actually secrete glucagon from the gut (see below), causing misleading results.
In the authors’ laboratory, we have always used some form of sample pretreatment, typically ethanol
extraction (70–75% vol/vol final) [16]. The recovery after extraction is not 100% (rather around 70%),
but is rather constant, and effectively removes the interference. Using this procedure and high affinity
C-terminal antisera, the plasma concentration of glucagon typically falls from 7–10 mol/L in the fasting
state down to around 1 pmol/L [42], consistent with the near complete cessation of glucagon secretion
from isolated perfused pancreas preparation exposed to high glucose concentrations. The problem
with nonspecific interference (noted fx with the 30 K assay as well as the previous Unger assays and
with most commercial assays) is that the high baseline concentration is not only inaccurate but also to
some extent blurs dynamic responses [42,43].
3.2. Other Important Factors
The assays are usually performed in conventional buffers, but because glucagon in dilution
(like many peptides) sticks to glassware and plastics, some carrier, usually albumin, must be added.
The quality of the albumin is critical, because many albumin preparations are contaminated with
enzymes that may attack particularly the tracer. Today pure, recombinant albumin is available.
Additionally, the method of separation is critical, and all components must be checked for interference
in the assay. The same applies to the employed glassware.
4. The Enzyme-Linked Immunosorbent Assay, ELISA
A sandwich ELISA is the ideal solution to the specificity problem of the glucagon assay. For this,
a pair of antisera are required that are “terminal wrapping”, meaning that their binding site is the free
terminus of the molecule, such that any modification of the terminus, prolongation or truncation, leads
to complete loss of binding to the antibody. As discussed above, the many clones generated during the
immunization process are incompatible with the required specificity; therefore, monoclonal antibodies
are generally necessary for such assays, and since they also need to have a reasonable affinity for
the ligand, the development of a suitable pair of antibodies is really challenging. Therefore, it was
a considerable advance when a high quality sandwich assay was finally developed by the company
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Mercodia [44], soon to be followed by other companies. Inherent in the sandwich technology is a
lesser sensitivity to matrix effects. Moreover, with sandwich ELISA technology, another important
problem was also solved: the volume requirements could also be minimized. This is essential
because the traditional radioimmunoassays require larger volumes, 100 µL or more, particularly if
extraction is applied, making it virtually impossible to measure glucagon concentrations in rodents,
especially in mice [45]. This unfortunately means that most reported values obtained in mice with
conventional techniques may not be accurate. The performance of the new sandwich ELISAs has been
compared in a couple of studies using C-terminal radioimmunoassays (with extraction), showing very
similar results. The Mercodia glucagon assay comes in two versions: A 10 µL version particularly
suited for mouse studies and a 25 µL version for human use. The antisera are not the same, and to
ensure enough sensitivity in the 10 µL assay, a pair of antibodies showing some cross-reaction with
oxyntomodulin had to be used, resulting in a cross-reaction by oxyntomodulin in this assay of about
10% (personal communication). This may play a role in studies involving intestinal stimulation,
whereas it may be suitable for studies not involving the GI tract. Otherwise, it is important to follow
the instructions provided by the manufacturers. Failure to do so may result in untoward crossreactions
and inaccurate measurements.
With the sandwich technology, it is of course also possible to measure other proglucagon products,
and a sandwich ELISA for proglucagon 1–61 was recently described [46]. The secretion of PG 1–61 is
particularly prominent during strong stimulation of the alpha cells, suggesting that it may act as an
indicator of alpha cell stress. As mentioned, this component is particularly prevalent in patients with
renal disease, but an explanation for this finding has not been found thus far [32].
Additionally, the gut derived peptides, oxyntomodulin and glicentin, may be measured accurately
with the sandwich technique. Note that the first commercial oxyntomodulin assay (from Phoenix) was
grossly inaccurate, yielding results which were about 1000-fold wrong [47]. Accurate oxyntomodulin
assays are not commercially available yet to our knowledge [43].
5. Mass Spectrometry
Mass-spectrometry is, by some, called the ‘golden standard’. Mass-spectrometry analysis of small
non-abundant peptides (e.g., glucagon) may be performed by several different approaches, each with
limitations, sensitivity being the most obvious, but in fact also includes specificity. Why is that?
Bottom-up or shotgun mass-spectrometry is typically used to measure the plasma proteome and
uses specific proteases (or none) to increase sensitivity [48]. The problem is the complexity of the
proteome/peptidome also called the dynamic range. Albumin and immunoglobulins are the most
abundant proteins, whereas glucagon is among some of the lowest abundant peptides. It is therefore
necessary to get rid of the proteins to find the proglucagon peptides.
Four main factors contribute to the method’s ability to identify glucagon in a complex solution
like plasma.
(1) Enrichment strategy by antibodies may suffer from specificity challenges (because the specificity
then depends on the specificity of the applied antibodies), whereas chemical (solvent extraction) and
physical-chemical isolation (high performance liquid chromatography or solid phase extraction) may
cause insensitivity due to the inherent losses of the peptide of interest (recovery problems).
(2) Flow rate of the liquid chromatography, ‘number of precursor ions per time unit’, is important;
by slowing this, one has a greater chance of identifying the peptide of interest.
(3) The acquisition of data (called data dependent and independent acquisitions) is crucial as this
sets the ‘boarder’ from what gets analyzed and what that does not in the mass-spectrometry.
(4) The search strategy (search engine, including variables as stringency that affect the risk/chance
of concluding that peptide A is endogenously present in the plasma and not generated during the
sample preparation (e.g., during reduction/alkylation)). MaxQuant is the most applied tool worldwide
but Peaks is also frequently used. Increasing the search frame (unbiased versus biased) is proportional
to the ‘computer power’, and hence the time required. Therefore, searching for the (mass of the)
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glucagon sequence alone may lead to bias, as posttranslational modifications may change the molecular
weight and hence the identification of the peptide.
Top-down or targeted proteomics (typically using a time-of flight instrument) had, until recently,
limited sensitivity, but with the introduction of the TimsTOF by Bruker [49], this may change. In this
setup, enrichment is not only mandatory for detection of peptides like glucagon in plasma but may
also be a major limitation due to e.g., differential recovery of peptide a. This approach may together
with selected reaction monitoring (SRM) constitute a strong tool for targeted mass-spectrometry
but may suffer from the lack of specificity of the enrichment method used (e.g., antibodies against
proglucagon) [50].
Collectively, mass-spectrometry is a powerful tool for evaluating the structure of a peptide or
protein in plasma or tissue, but as the technology suffers from sensitivity challenges, it cannot be used
to rule out or exclude the existence of e.g., glucagon in a given sample [51]. On the other hand, if
the samples do contain glucagon-like peptides above the detection limits of the method, it is more
accurate than an immunoassay to examine the heterogeneity/sequence of e.g., glucagon. As a method
of quantification, on the other hand, mass spectrometry has its own problems.
6. How to Evaluate the Performance of a Glucagon Assay?
The usual criteria for assay validation may be applied: precision must be good; usually intra-assay
coefficients of variation will be less than 10% (in our hands usually below 6%), but inter-assay variation
may be a little higher (>10%). This means that it is important always to include quality controls and
that samples that are to be compared should be analyzed together. Sensitivity must be high, allowing
measurements down to 1 pmol/L. This is important, since the secretory performance of the alpha cells
(the estimation of which is the purpose of all glucagon measurements) should not only be judged
from their capacity to increase secretion in response to amino acids (the arginine test), but also show
suppression by glucose [42]. Specificity towards the other proglucagon-derived peptides has been
discussed above and is of course essential for the measurements. The specificity is probably best
estimated by recovery experiments, where known amounts of the relevant peptides are added to
the assay, but it may also be relevant to check in clinical experiments whether the assay performs as
expected (e.g., showing suppression during hyperglycemica and great stimulation after arginine in
healthy controls) [45]. Finally, there is the question of accuracy. Again, for this one, we may turn to
recovery and dilution experiments, where known amounts of added glucagon must be recovered; even
when added in small amounts to complex fluids such as plasma. Recovery studies using buffer as
matrix are insufficient [43]. One way of testing accuracy is to compare performance against an accurate
analysis. The question is whether an accurate analysis exists. Mass spectrometry has been proposed
to represent the ultimate truth, but this is naturally not correct, since sample pretreatment may be
associated with major and variable losses of analyte, while the sensitivity of the methods usually does
not allow unbiased analysis as discussed above. Thus, mass spectrometry has its own sensitivity and
accuracy problems.
Currently, there are important ongoing discussions regarding some of these issues, mainly focused
on the question whether glucagon is indeed secreted from the gut or exclusively from the pancreas.
In one study, glucagon was measured in pancreatectomized patients after oral glucose using both
C-terminal radioimmunoassays, a sandwich ELISA and mass spectrometry (using physical-chemical
enrichment strategy and an unbiased search frame), confirming paradoxical rises after oral glucose,
in parallel with secretion of enteroglucagons and GLP-1 (illustrating the stimulation of the L-cell) [36].
These findings were in agreement with earlier reports on intestinal production of glucagon after
total pancreatectomy in humans, as identified by C-terminal radioimmunoassay and size-exclusion
chromatography [52]. This was interpreted to perhaps indicate aberrant processing of intestinal
proglucagon in these patients, whose L-cells were more than usually stimulated because of the surgical
reconstruction of the upper GI tact after the operation, in a manner resembling Roux-en-Y gastric bypass.
In further studies, glucagon was also identified in intestinal extracts from these patients [53]. Another
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group looked at gastrectomized patients that had a similar reconstruction with overstimulation of the
intestinal L-cells, and found secretion using the Mercodia assay (the version of the kit is not mentioned
in the study), but not if a more thorough alternative washing protocol was applied [54]. They also
used mass spectrometry to support their findings, and concluded that glucagon was not found in
these samples. In a final study, the two protocols for the sandwich ELISA were thoroughly compared
using clinical samples from Roux-en-Y patients and controls, and also included mass spectrometry
analysis. In this study, results from mass spectrometry and the ELISA using the alternative protocol
correlated well, whereas the correlation with results obtained with the traditional protocol was poor in
RYGB operated patients. However, it was also clear that the alternative protocol was associated with
systematically lower readings suggesting that analyte had been lost by this procedure. This was in
particular the case for protein-induced secretion of glucagon which was completely lost [55].
From these considerations it is clear that in samples with potentially high values of alternative
proglucagon products, great caution still needs to be exerted.
7. Recommendation for Measurement of Glucagon in Plasma
Preanalytical considerations, not presented in this paper, but covered elsewhere [56,57], are
extremely important. To recap our recommendations:
• Use EDTA tubes for blood sampling and stored on ice until separation of plasma by temperature
controlled (5 degrees Celsius) centrifugation. Always use low adsorption tubes.
• If a protease inhibitor is added (DPP-4, aprotinin, or similar), it is important to do this consistently
across all samples—this seems to be most important for samples analyzed by ELISA, but the effect
in the glucagon assays is not clear. It is not clear whether the use of P800 tubes is advantageous.
• Aprotinin or trasylol does not seem to be required when plasma is analyzed by C-terminal assays.
Neprilysin inhibitors may increase circulating glucagon concentrations [58], but in EDTA plasma,
neprilysin is inactive; thus, inhibitors do not need to be added.
• Storage of plasma samples in low-absorbent material at −20 degrees Celsius.
• Freeze-thaw maximum 1 time.
• Minimize hemolysis.
• If extraction/’cleaning’ is required, consider to use solvent and not solid phase extraction due to
the poor recovery after solid phase extraction.
Analytical considerations:
• Check the recovery of both calibrator and purified glucagon peptide in the matrix intended for
use (mouse or human plasma).
• Test if the precision of the analysis allows single or duplicate measurements (duplicate is generally
advisable).
• Always follow the protocol by the manufacture.
• For ELISAs: consider the washing protocol and contact the vendor, but remember to focus on
the aim of the study, e.g., if cross-reactivity to other proglucagon peptides is expected (e.g., after
RYGB surgery), keep in mind you may lose the physiological dynamics regarding for example
amino acid stimulated glucagon secretion due to the reduced recovery of native glucagon after
intensified washing procedures.
• Classical C-terminal radioimmunoassay may be preferable for most purposes, but note that
proglucagon 1-61 will crossreact (check renal function). However, if volume is critical, a validated
sandwich ELISA is useful.
8. Conclusions
In this review, we have discussed the analytical challenges of measurement of plasma glucagon.
We have, in particular, focused on strengths and limitations of radioimmunoassays, ELISAs,
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and mass-spectrometry based detection methods for measurement of glucagon. Finally, we have
provided general guidelines for measurement of plasma glucagon that we hope may be helpful in the
field on glucagon biology and guide critical assessment of commercially available glucagon assays.
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